In this issue of Neuron, Kremeyer et al. describe a gain-of-function mutation of TRPA1 that produces a painful disorder, familial episodic pain syndrome. This discovery enlarges the list of ion channels that, when mutated, produce pain. The growing universe of ''channelopathic pain'' presents some interesting overarching concepts and questions.
When C.S. Lewis described pain as ''God's megaphone,'' he was referring to psychological pain. Physical pain, however, commands attention when it is present, and can be incapacitating. Pain occurs frequently and can be long-lasting and severe, for example, in association with diabetic neuropathy, postherpetic neuralgia, nerve injury, and traumatic limb amputation. Pain in these disorders is often unresponsive or only partially responsive to existing pharmacotherapies, so there is a pressing need for the development of more effective pain medications. In this issue of Neuron, Kremeyer et al. (2010) present a comprehensive analysis that links a gain-of-function mutation of TRPA1, a nonselective cation channel that functions as a sensor of environmental irritants, to a familial pain syndrome. This important study extends the universe of human ''channelopathic'' pain syndromes caused by ion channel mutations beyond the now well-established pain disorders associated with mutations of SCN9A, the gene that encodes voltage-gated sodium channel Na V 1.7.
As described by Kremeyer et al., a point mutation in the S4 transmembrane segment of TRPA1 produces a syndrome characterized by bouts of severe upper body pain, triggered by physical stress, cold, or fasting. These observations suggest that, for at least some painful disorders, TRPA1 antagonists may be useful as therapeutic agents, but they also raise interesting questions. The striking topographic pattern of pain affecting the arms and trunk is unusual and as enigmatic as the distal limb pain or lower body pain seen with Na V 1.7 channelopathies described below. We do not yet understand why, in these cases, a mutation of an ion channel that is expressed widely within primary sensory neurons should produce a spatially restricted pattern of pain. Possible explanations include regional expression of the mutated channel within sensory neurons innervating the affected part of the body, or a focal pattern of access to modulatory subunits or activating ligands. Alternatively, spatially differentiated patterns of expression of other channels in sensory neurons might modulate the response of these cells to the presence of the mutant channel. Different levels of expression of Na V 1.8 have been shown, for example, to exert a powerful cell background effect that strongly influences the impact of Na V 1.7 mutations on excitability in different types of neurons (Rush et al., 2006) . Discovery of this new syndrome enlarges the universe of ion channel mutations that can cause chronic somatic pain (Table 1) . Since 2004, several dozen different mutations of sodium channel Na V 1.7 have been shown to cause three distinct clinical syndromes in humans . Dominant gain-offunction missense mutations in Na V 1.7 cause inherited erythromelalgia (Yang et al., 2004) , which is characterized by episodes of excruciating burning pain and redness in the distal extremities, triggered by mild warmth. In almost all cases, these mutations shift activation in a hyperpolarizing direction, slow deactivation, and increase the channel's response to slow subthreshold depolarizations (Cummins et al., 2004) . A second syndrome, called paroxysmal extreme pain disorder (PEPD), is characterized by perirectal, periocular, and perimandibular pain, triggered by perineal stimulation, and is caused by another set of dominant gainof-function mutations of Na V 1.7, which impair inactivation; as a result of the inactivation defect, these mutant channels produce an enhanced persistent current, which in many cases is reduced by the sodium channel blocker carbamazepine, a result that explains the favorable response of patients with PEPD to treatment with this medication. Complementing this duo of gain-of-function syndromes, a recessive loss-of-function syndrome, Na V 1.7-related congenital insensitivity to pain, has now also been identified (Cox et al., 2006) . In this disorder, affected individuals lack functional Na V 1.7 channels and do not feel pain, thus accruing painless fractures, painless burns, etc.
Thus far, causative mutations of other members of the TRP and sodium channel families, including Na V 1.8 and Na V 1.9 (which, like Na V 1.7, acts as a threshold channel, amplifying small depolarizing inputs), and of other types of channels, have not been reported in patients with chronic somatic pain. Na V 1.8 and Na V 1.9 are preferentially expressed within dorsal root ganglion neurons, particularly nociceptors, and it might have been expected that mutations in these channels would alter pain perception or produce chronic pain. The absence of reports of mutations of Na V 1.8 and Na V 1.9 linked to pain syndromes could represent an ascertainment bias, since families with inherited pain syndromes are very rare; patients with the known Na V 1.7-and TRPA1-related pain syndromes describe the pain as excruciating, and pain of this severity might interfere with reproductive behavior. But it also might be speculated that mutations of Na V 1.8 and Na V 1.9 are less likely to produce pain. The voltage-dependence of Na V 1.8 is shifted 20-30 mV in a depolarizing direction relative to other sodium channels. Thus, Na V 1.8 requires more depolarization to activate but is relatively resistant to inactivation; once activated, it contributes the majority of the inward transmembrane current underlying the rising phase of the action potential and supports repetitive firing in response to sustained depolarization (Renganathan et al., 2001) . The presence of wild-type Na V 1.8 can support firing at very high frequencies within permissive cell backgrounds (Waxman, 2006) , and it is possible that gain-of-function mutations of Na V 1.8 do not enhance the activity of nociceptors because other sodium channels such as Na V 1.7 set threshold in these primary sensory neurons, with still other conductances (such as potassium channels) or cell-specific modulation setting upper limits on firing frequency. Na V 1.9 has been shown to regulate nociceptor excitability. However, this channel has a substantial effect on excitability even when present at 20%-40% of its normal levels, and this effect reaches an asymptote at levels well below those seen in primary sensory neurons (Herzog et al., 2001) , so that gain-of-function mutations might not always result in a significant increase in nociceptor threshold or firing rate.
Whether mutations of other ion channels can produce chronic pain is not yet clear. Nociceptors express multiple ion channels, including some that are also present within CNS neurons. A mutation of sodium channel Na V 1.3 (Holland et al., 2008) that increases the persistent and ramp currents produced by this channel and induces hyperexcitability and spontaneous firing in hippocampal neurons (Estacion et al., 2010) has been shown to produce epilepsy. It is well-established that Na V 1.3 accumulates within neuromas, including painful human neuromas (Black et al., 2008) . It would be interesting, in this regard, to know whether individuals housing this gain-of-function Na V 1.3 mutation have an increased propensity to develop neuropathic pain following nerve injury.
Finally, we are led to inquire as to whether sporadic cases of chronic pain, due to founder or de novo ion channel mutations, or pain syndromes associated with ion channel polymorphisms, are present within our population but have eluded detection. Several cases of sporadic erythromelalgia due to de novo mutations in SCN9A have been described . Whether other mutations in Na V 1.7, in other sodium or TRP channels, or in other ion channels, would be identified via DNA profiling of larger numbers of patients with sporadic pain syndromes is not yet clear. A polymorphism of SCN9A, which produces the R1150W substitution in Na V 1.7, is present in more than 15% of control Caucasian chromosomes and has been shown to increase nociceptor excitability (Estacion et al., 2009 ). This polymorphism has now been linked in genome-wide association studies to enhanced pain sensitivity and an apparent increase in pain associated with disorders such as osteoarthritis, spinal root nerve injury, and phantom pain after limb amputation (Reimann et al., 2010) . Other polymorphisms that alter pain perception, or the likelihood of developing chronic pain in various injury or disease states, are probably lurking within the human genome.
Neuroscientists have traditionally categorized pain as ''nociceptive'' (triggered by the presence of a noxious stimulus), ''neuropathic'' (due to dysfunction of the nervous system), or ''inflammatory'' (resulting from aberrant inflammatory activation of nociceptors). An increasing number of peripheral injuries have been shown to trigger changes in channel expression and excitability of neurons along the pain-signaling pathway, raising the question of whether most chronic pain has a neuropathic component. The discovery of a growing list of pain disorders, produced by mutations of ion channels, indicates that some pain disorders are driven by intrinsic gain-of-function changes in ion channels, and adds Tight control of synapse formation ensures that neurons connect to appropriate targets. In this issue of Neuron, Klassen et al. identify ARL-8 GTPase as a regulator of presynaptic assembly. Without ARL-8, presynaptic material aggregates en route to its destination, suggesting that ARL-8 acts like a dispersant to prevent premature synaptic assembly in the axon.
Much attention has been paid to signals that initiate synaptogenesis. Contact between an axon and its proper target causes the postsynaptic membrane to accumulate receptors and scaffolding and causes the presynaptic varicosity to acquire an active zone and vesicle cluster (Jin and Garner, 2008; Owald and Sigrist, 2009) . But focusing on signals for synapse building can overlook two equally important aspects of synaptogenesis: the infrastructure of the neuron that delivers the building materials to their site of assembly and the negative control mechanisms that prevent synapses from assembling where they should not. In this issue of Neuron, Klassen et al. (2010) describe a C. elegans mutant that highlights these aspects of synaptogenesis and points to a mechanism for restricting presynaptic specializations to their proper positions.
Presynaptic proteins are synthesized in the soma and transported along axons by specialized motors. The components travel in at least two classes of transport vesicle. One contains the components of synaptic vesicles and a second, often called a piccolo/bassoon transport vesicle, contains components of the active zone (Jin and Garner, 2008; Owald and Sigrist, 2009 ). These components are delivered principally by the kinesin-3 motors, which are distinct from those that support axon outgrowth and pathfinding (Pack-Chung et al., 2007) . Disruption of this transport can prevent synapse
